sFlt-1: A Pivotal Biomarker for Pregnancy-Related Risk Prediction and ANT BIO PTE. LTD.'s Antibody Solutions

1. Concept: Soluble Fms-like Tyrosine Kinase 1 (sFlt-1) and Preeclampsia

Soluble Fms-like Tyrosine Kinase 1 (sFlt-1), also referred to as soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), is a glycoprotein with tyrosine kinase activity. It belongs to the soluble splice variant family of VEGFR-1, characterized by containing only the extracellular ligand-binding domain while lacking the cytoplasmic domain and transmembrane helix. The Flt-1 gene encodes mRNA with 30 exons, and its precursor mRNA undergoes alternative splicing to generate multiple soluble variants, including sFlt-1-1-i13, sFlt-1-1-i14, sFlt-1-1-i15a, and sFlt-1-1-i15b—all of which exhibit antagonistic effects on placental growth factor (PlGF).

Preeclampsia is an acute and life-threatening pregnancy complication, occurring after 20 weeks of gestation with clinical manifestations of new-onset hypertension, proteinuria, and potential progression to eclampsia (generalized convulsions). It affects 3% to 7% of pregnancies worldwide, leading to preterm birth in 15% of affected cases and accounting for 42% of maternal deaths. As a key biomarker associated with preeclampsia, sFlt-1 plays a critical role in the pathogenesis, diagnosis, and risk prediction of this disorder, linking placental function to maternal vascular health.

2. Research Frontiers of sFlt-1 in Pregnancy-Related Risk Assessment

Recent research advances have solidified sFlt-1’s status as a core biomarker in maternal-fetal medicine. A major frontier is the clinical validation of the sFlt-1/PlGF ratio for precise risk stratification of preeclampsia and fetal growth restriction (FGR). Contemporary studies focus on refining gestational phase-specific cutoff values to enhance predictive accuracy across different trimesters. Another key direction involves exploring the molecular mechanisms underlying sFlt-1 overproduction in trophoblasts, aiming to identify novel therapeutic targets for preventing preeclampsia. Additionally, the development of high-sensitivity detection tools for sFlt-1—such as advanced ELISA kits and monoclonal antibody-based assays—has become a priority to enable early screening and real-time monitoring of pregnancy-related risks. Furthermore, integrating sFlt-1/PlGF ratio data with clinical parameters (e.g., blood pressure, maternal age) is emerging as a promising strategy to improve the predictive value of preeclampsia screening programs.

3. Research Significance of sFlt-1 in Maternal and Fetal Health

The study of sFlt-1 holds profound significance for addressing unmet needs in pregnancy care:

• Early risk prediction: Elevated sFlt-1 levels and abnormal sFlt-1/PlGF ratios precede clinical symptoms of preeclampsia, enabling timely intervention to prevent severe complications.
• Accurate diagnosis and differential diagnosis: The sFlt-1/PlGF ratio helps distinguish preeclampsia from other pregnancy-related hypertensive disorders, reducing misdiagnosis and unnecessary treatment.
• Disease severity assessment: The ratio correlates positively with preeclampsia severity, guiding clinicians in optimizing management strategies and resource allocation.
• Improved maternal and fetal outcomes: By facilitating early detection and targeted interventions, sFlt-1-based screening reduces pregnancy-related mortality and morbidity, as well as the risk of preterm birth and fetal growth restriction.
• Mechanistic insights: Research on sFlt-1’s role in placental angiogenesis provides a foundation for developing novel preventive and therapeutic approaches for preeclampsia.

4. Relevant Mechanisms, Research Methods and Product Applications

4.1 Core Mechanisms of sFlt-1 in Preeclampsia Pathogenesis

sFlt-1 is predominantly produced by placental trophoblasts. In preeclampsia, abnormal overproduction and release of sFlt-1 into the maternal circulation disrupt normal vascular homeostasis:

• sFlt-1 competitively binds to VEGF-A and PlGF, neutralizing their biological activity and inhibiting downstream signaling pathways.
• This antagonism suppresses placental angiogenesis and impairs vascular remodeling, leading to placental hypoperfusion.
• The compromised placenta further secretes excess sFlt-1, creating a vicious cycle that induces maternal endothelial dysfunction and systemic inflammation—key drivers of preeclampsia development and progression.

4.2 Key Research Methods for sFlt-1 Detection

Research and clinical applications of sFlt-1 rely on sensitive and specific detection techniques:

• ELISA (Enzyme-Linked Immunosorbent Assay): The gold standard for quantifying serum sFlt-1 and PlGF levels, enabling calculation of the sFlt-1/PlGF ratio. It offers high sensitivity, specificity, and reproducibility, suitable for large-scale screening.
• Monoclonal antibody-based assays: Utilize high-specificity antibodies to capture and detect sFlt-1, supporting both quantitative and qualitative analysis.
• Molecular biology techniques: RT-PCR for measuring sFlt-1 mRNA expression in placental tissues, providing insights into transcriptional regulation of sFlt-1 production.
• Clinical validation studies: Prospective and retrospective cohort studies to evaluate the predictive value of sFlt-1/PlGF ratios across different gestational stages and patient populations.

4.3 Clinical Value of sFlt-1/PlGF Ratio

The sFlt-1/PlGF ratio has been endorsed by clinical guidelines (e.g., "Guidelines for the Diagnosis and Treatment of Hypertensive Disorders in Pregnancy 2020") as a robust biomarker for preeclampsia and FGR:

• Short-term prediction: A cutoff value of 38 provides a negative predictive value of 99.3% for excluding preeclampsia within one week, and a positive predictive value of 36.7% for predicting onset within four weeks.
• Gestational phase-specific diagnosis:
• Ratio < 33: Rules out preeclampsia.
• Ratio > 85: Diagnostic of early-onset preeclampsia (20–33+6 weeks).
• Ratio > 110: Diagnostic of late-onset preeclampsia (34 weeks to delivery).
• Disease severity correlation: Higher ratios are associated with more severe preeclampsia and poorer maternal-fetal outcomes.

4.4 Product Applications of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. delivers high-performance antibody solutions for sFlt-1 research and clinical detection through its Starter sub-brand—specializing in recombinant antibodies. All products are developed using advanced recombinant rabbit/mouse monoclonal antibody platforms, validated for sensitivity and specificity, and comply with EU 98/79/EC, ISO9001, and ISO13485 certifications. Key offerings include:

• sFlt-1 Recombinant Rabbit mAbs: Catalog numbers S0B3142 (SDT-233-2), S0B3141 (SDT-233-26-2), and S0B3140 (SDT-233-26) exhibit exceptional sensitivity (detection limit < 10 pg/ml) and specificity for human sFlt-1. These antibodies enable accurate quantification of sFlt-1 in serum and placental samples, supporting ELISA development, Western blot analysis, and immunohistochemistry.
• IGFBP4 Recombinant Antibodies: Catalog numbers S0B3144 (Rabbit, SDT-187-35) and S0B3143 (Mouse, SDT-185-H182) complement sFlt-1 research by targeting IGFBP4—a protein involved in maternal-fetal metabolism and pregnancy-related disorders.

These antibodies provide reliable raw materials for developing diagnostic kits and research tools, empowering global partners to deliver accurate sFlt-1 detection services and advance preeclampsia research.

5. Brand Mission of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. is dedicated to empowering global life science research and clinical practice through high-quality, innovative reagents and professional services. As a leading provider of life science solutions, the company offers a comprehensive portfolio including antibodies, recombinant proteins, ELISA kits, and general laboratory reagents, with three specialized sub-brands: Absin (general reagents and kits), Starter (antibodies), and UA (recombinant proteins). Leveraging advanced R&D platforms—including recombinant antibody development (rabbit/mouse monoclonal), protein expression systems (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA, and PTM Pan-Modification Antibody platforms—ANT BIO PTE. LTD. adheres to the principles of "precision, reliability, and customer-centricity." The company strives to deliver cost-effective products and tailored support to researchers, clinicians, and biopharmaceutical partners, accelerating the translation of scientific discoveries into improved patient care and advancing global maternal and fetal health.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.